Quote | Chardan Healthcare Acquisition Corp. (NYSE:PHGE)
Last: | $0.3399 |
---|---|
Change Percent: | 0.0% |
Open: | $0.3465 |
Close: | $0.3399 |
High: | $0.35 |
Low: | $0.315 |
Volume: | 126,163 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Chardan Healthcare Acquisition Corp. (NYSE:PHGE)
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
Message Board Posts | Chardan Healthcare Acquisition Corp. (NYSE:PHGE)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $PHGE 43% v2,7M c.575 f35,958M H.69 ML.28 LL.132 | znewcar1 | investorshangout | 03/01/2023 10:05:08 PM |
$PHGE: Agreement with Maruho for Atopic Dermatitis Product | makinezmoney | investorshub | 10/13/2021 11:48:06 AM |
News, Short Squeeze, Breakout and More Instantly...
Chardan Healthcare Acquisition Corp. Company Name:
PHGE Stock Symbol:
NYSE Market:
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously discl...